PB4 Patient Perspectives on Implementation of a Long-Acting Injectable Antiretroviral Therapy Regimen in HIV US Healthcare Settings: Final Month 12 Results from the CUSTOMIZE Study

J Flamm,C Garris,R D'Amico,M Dalessandro,C.A Mchorney,S.G Mansukhani,P Benson,B Thedinger,D Salazar,N Tanda,J Fricker,M Czarnogorski

doi:10.1016/j.jval.2021.04.070

PB4 Patient Perspectives on Implementation of a Long-Acting Injectable Antiretroviral Therapy Regimen in HIV US Healthcare Settings: Final Month 12 Results from the CUSTOMIZE Study

J Flamm, C Garris + Show 10 more

Open Access

https://doi.org/10.1016/j.jval.2021.04.070

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jun 1, 2021
Citations: 2	License type: publisher-specific-oa

Affiliation: Kaiser Permanente, Triangle, Kansas City CARE Clinic, University of Florida, GlaxoSmithKline (United Kingdom)

#US Healthcare Settings #US Healthcare + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Cabotegravir and rilpivirine long-acting (CAB+RPV LA) administered by monthly injection has demonstrated non-inferiority compared to standard daily oral antiretroviral therapy (ART). Patient perspectives after one year of implementation of CAB+RPV LA in US healthcare settings were evaluated in an innovative implementation-effectiveness study (CUSTOMIZE).

Full Text